Oklahoma Health Care Authority

Drug Utilization Review Board
(DUR Board)
Meeting – October 11, 2023 @ 4:00pm
at the
Oklahoma Health Care Authority (OHCA)
4345 N. Lincoln Blvd.
Oklahoma City, Oklahoma 73105

NOTE: ***The DUR Board will meet at 4:00pm at OHCA (see address above). There will be Zoom access to this meeting; however, Zoom access will be set up in view-only mode with no voting, speaking, video, or chat box privileges. Zoom access will allow for viewing of the presentation slides as well as audio of the presentations and discussion during the meeting; however, the DUR Board meeting will not be delayed or rescheduled due to any technical issues that may arise.***

AGENDA

Discussion and action on the following items:

Items to be presented by Dr. Muchmore, Chairman:

1. **Call to Order**

A. Roll Call – Dr. Adams

DUR Board Members:

Mr. Kenneth Foster –	participating in person
Dr. Megan Hanner –	participating in person
Dr. John Muchmore –	participating in person
Dr. Lee Muñoz –	participating in person
Dr. James Osborne –	participating in person
Dr. Edna Patatanian –	participating in person
Dr. Vineetha Thomas –	participating in person
Dr. Beth Walton –	participating in person

Viewing Access Only via Zoom:

Please register for the meeting at:
https://www.zoomgov.com/webinar/register/WN_GBU9Q-svQteascYrpAryxA
After registering, you will receive a confirmation email containing information about joining the webinar.

Or join by phone:
Dial: +1-602-753-0140 or +1-669-219-2599
Webinar ID: 160 823 0246
Passcode: 994690

Public Comment for Meeting:

- Speakers who wish to sign up for public comment at the OHCA DUR Board meeting may do so in writing by visiting the DUR Board page on the OHCA website at www.oklahoma.gov/ohca/about/boards-and-committees/drug-utilization-review/dur-board and completing the Speaker Registration Form. Completed Speaker Registration forms should be submitted to DURPublicComment@okhca.org. Forms must be received after the DUR Board agenda has been posted and no later than 24 hours before the meeting.
- The DUR Board meeting will allow public comment and time will be limited to 40 minutes total for all speakers during the meeting. Each speaker will be given 5 minutes to speak at the public hearing. If more than 8 speakers properly request to speak, time will be divided evenly.
- Only 1 speaker per manufacturer will be allowed.
- Any speakers who sign up for public comment must attend the DUR Board meeting in person at OHCA (see above address). Public comment through Zoom will not be allowed for the DUR Board meeting.

Items to be presented by Dr. Muchmore, Chairman:

2. **Public Comment Forum**
   A. Acknowledgement of Speakers for Public Comment

Items to be presented by Dr. Muchmore, Chairman:

3. **Action Item – Approval of DUR Board Meeting Minutes – See Appendix A**
   A. September 13, 2023 DUR Board Meeting Minutes
   B. September 13, 2023 DUR Board Recommendations Memorandum
   C. Correspondence

Items to be presented by Dr. O'Halloran, Dr. Reynolds, Dr. Muchmore, Chairman:

4. **Update on Medication Coverage Authorization Unit/Fall Pipeline Update – See Appendix B**
   A. Pharmacy Help Desk Activity for September 2023
   B. Medication Coverage Activity for September 2023
   C. Fall Pipeline Update

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

5. **Action Item – Vote to Prior Authorize Rebyota® (Fecal Microbiota, Live-jslm) and Vowst™ (Fecal Microbiota Spores, Live-brpk) and Update the Approval Criteria for Zinplava™ (Bezlotoxumab) – See Appendix C**
   A. Market News and Updates
   B. Product Summaries
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Daugherty, Dr. Muchmore, Chairman:

6. **Action Item – Vote to Prior Authorize Orserdu™ (Elacestrant) and Update the Approval Criteria for the Breast Cancer Medications – See Appendix D**
   A. Market News and Updates
   B. Product Summary
   C. College of Pharmacy Recommendations

Items to be presented by Dr. Teel, Dr. Muchmore, Chairman:

7. **Action Item – Annual Review of Imcivree® (Setmelanotide) – See Appendix E**
   A. Current Prior Authorization Criteria
   B. Utilization of Imcivree® (Setmelanotide)
   C. Prior Authorization of Imcivree® (Setmelanotide)
   D. Market News and Updates
   E. College of Pharmacy Recommendations
   F. Utilization Details of Imcivree® (Setmelanotide)

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

8. **Action Item – Annual Review of Hepatitis C Medications – See Appendix F**
   A. Current Prior Authorization Criteria
   B. Utilization of Hepatitis C Medications
   C. Prior Authorization of Hepatitis C Medications
   D. Market News and Updates
   E. College of Pharmacy Recommendations
   F. Utilization Details of Hepatitis C Medications

Items to be presented by Dr. Daugherty, Dr. Muchmore, Chairman:

9. **Annual Review of Myeloproliferative Neoplasm Medications and 30-Day Notice to Prior Authorize Ojjaara (Momelotinib) – See Appendix G**
   A. Current Prior Authorization Criteria
   B. Utilization of Myeloproliferative Neoplasm Medications
   C. Prior Authorization of Myeloproliferative Neoplasm Medications
   D. Market News and Updates
   E. Ojjaara (Momelotinib) Product Summary
   F. College of Pharmacy Recommendations
   G. Utilization Details of Myeloproliferative Neoplasm Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

10. **Annual Review of Anemia Medications and 30-Day Notice to Prior Authorize Jesduvroq™ (Daprodustat) – See Appendix H**
    A. Current Prior Authorization Criteria
    B. Utilization of Anemia Medications
    C. Prior Authorization of Anemia Medications
    D. Market News and Updates

E. Jesduvroq™ (Daprodustat) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Anemia Medications

Items to be presented by Dr. Wilson, Dr. Muchmore, Chairman:

11. Annual Review of Targeted Immunomodulator Agents and 30-Day Notice to Prior Authorize Idacio® (Adalimumab-aacf), Litfulo™ (Ritlecitinib), Tofidence™ (Tocilizumab-bavi), Yuflyma® (Adalimumab-aaty), and Yusimry™ (Adalimumab-aqvh) – See Appendix I

A. Current Prior Authorization Criteria
B. Utilization of Targeted Immunomodulator Agents
C. Prior Authorization of Targeted Immunomodulator Agents
D. Market News and Updates
E. Product Summaries
F. College of Pharmacy Recommendations
G. Utilization Details of Targeted Immunomodulator Agents

Items to be presented by Dr. Moss, Dr. Muchmore, Chairman:

12. Annual Review of Muscular Dystrophy Medications and 30-Day Notice to Prior Authorize Elevidys (Delandistrogene Moxeparvovec-rokl) – See Appendix J

A. Current Prior Authorization Criteria
B. Utilization of Muscular Dystrophy Medications
C. Prior Authorization of Muscular Dystrophy Medications
D. Market News and Updates
E. Elevidys (Delandistrogene Moxeparvovec-rokl) Product Summary
F. College of Pharmacy Recommendations
G. Utilization Details of Muscular Dystrophy Medications

Items to be presented by Dr. Reynolds, Dr. Muchmore, Chairman:

13. Annual Review of Spinal Muscular Atrophy (SMA) Medications – See Appendix K

A. Current Prior Authorization Criteria
B. Utilization of SMA Medications
C. Prior Authorization of SMA Medications
D. Market News and Updates
E. College of Pharmacy Recommendations
F. Utilization Details of SMA Medications

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

14. 30-Day Notice to Prior Authorize Veopoz™ (Pozelimab-bbfg) – See Appendix L

A. Introduction
B. Veopoz™ (Pozelimab-bbfg) Product Summary
C. College of Pharmacy Recommendations

Items to be presented by Dr. O'Halloran, Dr. Muchmore, Chairman:

15. **U.S. Food and Drug Administration (FDA) and Drug Enforcement Administration (DEA) Updates – See Appendix M**

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman:

16. **Future Business* (Upcoming Product and Class Reviews)**
    A. Asthma and Chronic Obstructive Pulmonary Disease (COPD) Maintenance Medications
    B. Atopic Dermatitis Medications
    C. Injectable and Vaginal Progesterone Products
    D. Multiple Myeloma Medications

    *Future product and class reviews subject to change.

17. **Adjournment**

NOTE: An analysis of the atypical [Aged, Blind, and Disabled (ABD)] patient subgroup of the Oklahoma Medicaid population has been performed pertaining to all recommendations included in this DUR Board meeting packet to ensure fair and knowledgeable deliberation of the potential impact of the recommendations on this patient population.